Real-time monitoring of oxidative products from in vitro cell-biomaterial interaction using chemiluminescence

• US 5,294,541 A
• Filed: 07/13/1992
• Issued: 03/15/1994
• Est. Priority Date: 09/21/1989
• Status: Expired due to Term

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Inventors: Mueller, Edward P., Kaplan, David S., Picciolo, Grace L.
• Primary Examiner(s): Nucker, Christine M.
• Assistant Examiner(s): PRESTON, DAVID
• Application Number:
  US07/912,590
• Time in Patent Office: 610 Days
• Field of Search: 435/29, 435/39
• US Class Current: 435/29
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5014 for testing toxicity

Abstract

A chemiluminescence method for continuously monitoring in real time the generation of oxidative products such as hydrogen peroxide and superoxide from in vitro cell-biomaterial interactions using cell lines such as Human Leukemic cells (HL-60); tumor cell line hybridomas; cells lacking the respiratory burst such as Chronic Granulomatous Disease cells as controls; Monocytic cell lines; Primary Human cells such as monocytes, pmns, fibroblasts, endothelial cells; and whole and isolated blood cells. The oxidative products have the potential for the degradation of the biomaterial and thus this information can be used to aid in predicting the functional lifetime of the biomaterial when it is used to fabricate an implanted medical device. Further, this method may be used to determine the amount of activation of biological cells which is inferred from the amount of oxidative products. This activation level aids in the determination of the degree of the inflammatory response and thus influences the degree of acceptance of the biomaterial. Thus, toxicity and biocompatability tests could be supported by these measurements.

Claims

1. A method for analyzing in real time in vitro interactions between biological cells and biomaterial proposed for implantation which comprises:

introducing biological cells and biomaterial proposed for implantation into an environment for interaction, wherein said environment includes chemiluminescent probes which emit chemiluminescent light in the presence of oxidative products produced by said cells;

monitoring over real time the amount of chemiluminescent light produced by oxidative products of said cells in the presence of said biomaterial as a first measurement;

introducing a biological activator into said environment, wherein said biological activator causes the production of oxidative products;

monitoring over real time the amount of chemiluminescent light produced by oxidative products of said cells as a second measurement;

repeating the above steps under the same conditions except without the introduction of said biomaterial; and

measuring the amount of said oxidative products produced by the interaction between said biological cells and said biomaterial in said environment over real time based on a comparison of each of the first chemiluminescence measurements, respectively, and each of the second chemiluminescence measurements, respectively.

2. The method as defined in claim 1, wherein said oxidative products comprise hydrogen peroxide, superoxide, or combinations thereof.

3. The method as defined in claim 2, wherein said cells are selected from the group of cell lines consisting of Human Leukemic cells (HL-60), tumor cell line hybridomas, cells lacking the respiratory burst, Chromic Granulomatous Disease cells, Monocytic cell lines, Primary Human cells, whole blood cells, and isolated blood cells.

4. The method as defined in claim 3, wherein said chemiluminescent probes comprise particles which contain bound luminol or lucigenin.

5. The method as defined in claim 4, wherein said chemiluminescent light is monitored using a photometric instrument selected from the group consisting of a luminometer, a scintillation counter, a microscope photometer and a fiber optic sensor.

6. The method as defined in claim 5, wherein said biomaterial is selected from the group consisting of polyethylene, polyurethane and pyrolytic carbon.

7. The method as defined in claim 5, wherein said biomaterial is selected from the group consisting of metals, ceramics, bioresorbables, breakdown products of bioresorbables, hydroxyapatite, polyglycolic acids, nylon, silk, polymers, olyactic acids, glutaraldehyde and fixed naturally occurring materials.

8. The method as defined in claim 1, wherein said biological cells are selected from the group of cell lines consisting of Human Leukemic cells (HL-60), tumor cell line hybridomas, cells lacking the respiratory burst, Chromic Granulomatous Disease cells, Monocytic cell lines, Primary Human cells, whole blood cells, and isolated blood cells.

9. The method as defined in claim 8, wherein said Primary Human cells are selected from the group consisting of monocytes, polymorphonuclear leukocytes, fibroblasts and endothelial cells.

10. The method as defined in claim 1, which further comprises assessing biodegradation characteristics and biocompatability characteristics of said biomaterial by correlating the produced amount of said oxidative products with the measured characteristics of said material.

11. The method as defined in claim 1, which further comprises measuring the inflammatory reaction or the relative toxicity caused by said biomaterial by determining the produced amount of said oxidative products.

12. The method as defined in claim 1, which further comprises measuring suppression or enhancement of the phagocytosis response of the biological cells caused by the interaction between said cells and said biomaterial as an indication of a suppression or enhancement of the cell immune response by said material.

13. The method as defined in claim 1, which further comprises monitoring tumor cell killing in the presence of said material.

14. The method as defined in claim 1, which further comprise measuring the effects of leachables from said biomaterial on said biological cells.

15. The method as defined in claim 1, wherein said chemiluminescent probes comprise particles which contain bound luminol and lucigenin.

16. The method as defined in claim 15, wherein said particles comprise latex or glass beads.

17. The method as defined in claim 1, wherein said chemiluminescent light is monitored using a photometric instrument selected from the group consisting of a luminometer, a scintillation counter, a microscope photometer and a fiber optic sensor.

18. The method as defined in claim 1, wherein said biomaterial is selected from the group consisting of polyethylene, polyurethane and pyrolytic carbon.

19. The method as defined in claim 1, wherein said biomaterial is selected from the group consisting of metals, ceramics, bioresorbables, breakdown products of bioresorbables, hydroxyapatite, polyglycolic acids, nylon, silk, polymers, polylactic acids, glutaraldehyde and fixed naturally occurring materials.

20. The method as defined in claim 1, wherein said biological activator is selected from the group consisting of opsonized zymosan, phorbol-12-myristate-13-acetate and concanavalin A.

21. The method as defined in claim 1, wherein said chemiluminescent probes comprise luminol or lucigenin in solution.